Evommune, Inc. (NYSE:EVMN) Receives Consensus Rating of "Buy" from Brokerages

Key Points

• Thirteen brokerages give Evommune an average rating of Buy (1 sell, 1 hold, 8 buy, 3 strong buy) with an average 1‑year analyst target of $48.43.
• Evommune reported a sizable quarterly EPS miss—($1.43 loss per share vs. a $0.82 loss expected)—and analysts project roughly ($2.83) EPS for the fiscal year; the stock trades near $23.97 with a 52‑week range of $13.89–$33.20 and a market cap of about $863M.
• Several large institutions have recently taken new or larger stakes, notably EQT Fund Management (~$84.4M), RA Capital (~$59.2M), Pivotal bioVenture (~$33.0M), Nan Fung (~$24.7M) and JPMorgan (~$22.4M).

Evommune, Inc. (NYSE:EVMN - Get Free Report) has been given an average rating of "Buy" by the thirteen brokerages that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and three have assigned a strong buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $48.4286.

EVMN has been the subject of a number of research analyst reports. Clear Str raised shares of Evommune to a "strong-buy" rating in a report on Tuesday, March 17th. The Goldman Sachs Group upgraded shares of Evommune to a "buy" rating in a research report on Wednesday, January 7th. Weiss Ratings initiated coverage on shares of Evommune in a research report on Tuesday, February 3rd. They issued a "sell (e)" rating on the stock. Evercore reiterated an "outperform" rating and issued a $55.00 target price on shares of Evommune in a research report on Tuesday, February 10th. Finally, Morgan Stanley reiterated an "overweight" rating and issued a $54.00 target price on shares of Evommune in a research report on Wednesday, February 18th.

Evommune Price Performance

NYSE EVMN opened at $23.97 on Thursday. Evommune has a 52-week low of $13.89 and a 52-week high of $33.20. The company has a market cap of $863.29 million and a P/E ratio of -2.97. The stock's fifty day moving average is $25.17.

Evommune (NYSE:EVMN - Get Free Report) last posted its quarterly earnings data on Thursday, March 5th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.61). As a group, sell-side analysts predict that Evommune will post -2.83 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Evommune

A number of large investors have recently added to or reduced their stakes in EVMN. EQT Fund Management S.a r.l. bought a new stake in Evommune in the 4th quarter worth $84,395,000. RA Capital Management L.P. bought a new stake in Evommune in the 4th quarter worth $59,214,000. Pivotal bioVenture Partners Investment Advisor LLC bought a new stake in Evommune in the 4th quarter worth $32,989,000. Nan Fung Group Holdings Ltd bought a new stake in Evommune in the 4th quarter worth $24,670,000. Finally, JPMorgan Chase & Co. bought a new stake in Evommune in the 4th quarter worth $22,408,000.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients' quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.